Thu, Apr 17, 2014, 11:21 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

CEL-SCI Corporation Message Board

jpifer 222 posts  |  Last Activity: Apr 9, 2014 5:50 AM Member since: Oct 5, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    CEO exercises S warrants.

    by yankeesnyc27 Apr 7, 2014 6:26 PM
    jpifer@ymail.com jpifer Apr 9, 2014 5:50 AM Flag

    thanks yankee..170,000 shares at a 1.25 purchased...your post needs a bump for sure...

    Sentiment: Strong Buy

  • congrads to the shareholders.....

  • jpifer@ymail.com by jpifer Mar 19, 2014 3:07 AM Flag

    ..to the m warrant holders.exercisable before April this year?..The tune is up to 490,000 dollars....exercise price 1 buck...no so enticing..unless good news right around the corner...

    Sentiment: Strong Buy

  • Reply to

    new article....:) back to $2 ish !!

    by goodbrain007 Mar 13, 2014 6:01 PM
    jpifer@ymail.com jpifer Mar 13, 2014 6:36 PM Flag

    after hours looking good so far...thanks

  • jpifer@ymail.com jpifer Mar 13, 2014 1:27 PM Flag

    Kudos to Cvm believer....an excerpt from the video....(the endless number of cancer patients and types of cancer this could benefit would be amazing).............

    Sentiment: Strong Buy

  • jpifer@ymail.com jpifer Mar 7, 2014 8:40 AM Flag

    I hope the team did hit a home run..because they were very generous with the amount of shares acquired..in the latest Form 4s................

    Sentiment: Strong Buy

  • Reply to

    Wow,,,,,,, what up with pre market

    by jaulisio Mar 7, 2014 7:38 AM
    jpifer@ymail.com jpifer Mar 7, 2014 8:08 AM Flag

    thanks..this isn't a head fake ..volume 75000...

    Sentiment: Strong Buy

  • Reply to

    Did others see this?

    by thinkingonlygreen Feb 11, 2014 7:57 PM
    jpifer@ymail.com jpifer Feb 12, 2014 3:23 AM Flag

    ..thanks..What I gained from your find is the arbitration claim has backbone...phase 3 is getting its traction ..a very short amount of time required to see results on the Navy endeavor..also that the Corporate profile most likely took a position in Cel-Sci... cheers.............

    Sentiment: Strong Buy

  • ...knock em dead ...and good luck...

    Sentiment: Strong Buy

  • jpifer@ymail.com by jpifer Jan 24, 2014 3:58 AM Flag

    pits a short against a long.....not for the sake of mankind..but for the sake to say I was right and you were wrong...............................

  • jpifer@ymail.com by jpifer Jan 23, 2014 3:40 AM Flag

    the Teva deal in 2008, just before the Ergomed deal in 2013..his by far biggest most recent purchase on the open market is just before...?

    Sentiment: Strong Buy

  • Reply to

    Cel Sci Corp [CSCIW] files SEC Form 4

    by seecuriityman Jan 2, 2014 12:19 PM
    jpifer@ymail.com jpifer Jan 2, 2014 1:24 PM Flag

    ...that's something positive for sure....thx..

  • Reply to

    THEN AND NOW #3

    by yankeesnyc27 Oct 10, 2013 3:53 PM
    jpifer@ymail.com jpifer Oct 11, 2013 1:15 AM Flag

    ..have to bump the truth..........

    Sentiment: Strong Buy

  • has been placed....and a 10 mill dollar bet from Ergomed.......I'm feeling very confident right about now. This is far from over...............

    Sentiment: Strong Buy

  • jpifer@ymail.com by jpifer Sep 28, 2013 6:19 PM Flag

    ..if we only had the financing..Multikine would be in another cancer trial for another indication,a trial where the results wouldn't take as long as overall survival....I hope this becomes reality..

  • jpifer@ymail.com by jpifer Sep 18, 2013 2:14 AM Flag

    .LOS ANGELES — There were more than 13.7 million cancer survivors living in the United States in 2012 — nearly 2 million more than in 2008 — according to a cancer research report released Tuesday.

    But the numbers of Americans who die from cancer is also projected to rise as the nation's population ages, according to the American Association for Cancer Research's 2013 progress report. That makes it likely that cancer will soon be the No. 1 disease-related killer of Americans, outpacing heart disease.

    The report, which noted "amazing progress" in the fight against cancer even as it called for increased funding to promote still more scientific discoveries, summarized the current state of cancer.

    Much of the news was good. More people survive the disease than in the past: The report estimated that a million lives have been saved since 1990, thanks to advances in cancer prevention and therapy. Today, one in 23 Americans is a cancer survivor; in 1971, just one in 69 was. Death rates from malignant cancers declined 24.5 percent for men and 15.8 percent for women between 1990 and 2009.

    But the publication also noted that more than 1.6 million Americans will be diagnosed with cancer this year and that new cases worldwide are predicted to increase from 12.8 million in 2008 to 22.2 million in 2030. The global economic toll from the disease is higher than that of any other major disease, the report also said, making a case for increased funding for research.

    "Given that cancer is the most costly disease to our nation, and it is poised to become the No. 1 killer of Americans, it is urgent that we increase our investments in the scientific research needed to develop more effective interventions," the report said.

    One line of research highlighted in the report this year is cancer immunology: efforts to harness the body's own immune defenses to fight the disease. Dr. Drew Pardoll, director of the cancer immunology program at the Johns Hopkins Kimmel Comprehensive Cancer Center and a contributor to the report, described a number of advances in the field that had occurred in the last two to three years, including the FDA approvals of the prostate cancer vaccine Provenge in 2010 and of the drug ipilimumab to treat melanoma in 2011 (which "disables a parking break" that slows immune response in the body, he explained).

    Pardoll said that he thought immunotherapies, in combination with other treatments such as surgery and chemotherapy, had enormous potential to improve cancer survival — and that the research community as a whole was beginning to take note.

    "It's stunning to be in that moment of time when you see this inflection point or transition when immunotherapy has really become established as the fifth pillar of cancer treatment," Pardoll said.

  • jpifer@ymail.com by jpifer Aug 30, 2013 5:04 AM Flag

    the CEO does not know the word fail........people bust on his salary....his salary is peanuts compared to success ......it is going to get very interesting...........

    Sentiment: Strong Buy

  • ......now is a good time to postpone....I really don't think asking for more options..will go over so well.....

  • jpifer@ymail.com jpifer Jul 21, 2013 3:30 AM Flag

    Cel-Sci has a better chance at sucess in head and neck cancer than Inovio Pharm....SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO) announced today that it will stop further patient enrollment in its two Phase III pivotal studies for squamous cell head & neck cancer using its Selective Electrochemical Tumor Ablation (SECTA) investigational therapy based on a recommendation by the trial's independent data monitoring committee (DMC). In making its recommendation, the DMC expressed concern about efficacy and serious adverse events, including higher mortality rates on the SECTA arm of the study than on the surgery arm. In the DMC's opinion, based on the totality of the issues, the SECTA arm has an unfavorable benefit-to-risk profile, relative to the surgery arm. The DMC also suggested enrollment difficulties represent a possible challenge to meeting the goals of the trial.

    Dr. Paul Goldfarb, Consulting Medical Director overseeing the Phase III studies, said, "Based on the evidence of prior SECTA studies, we are surprised by the information and recommendation received from the DMC, the only body that has had access to the unblinded data. This new information was unexpected given the potential benefits of this technology. In respecting the DMC's concerns, we have accepted their recommendation to stop enrollment without further analysis. We will determine our next steps based on a thorough evaluation of the unblinded data."

    The DMC reviewed clinical data from 212 treated patients out of the targeted 400 patients defined in the clinical trial protocol. Inovio is notifying clinical investigators involved in the Phase III studies to terminate enrollment and is informing the Food & Drug Administration, . .....is that better Gary...Geesh.......

  • jpifer@ymail.com by jpifer Jul 20, 2013 11:49 AM Flag

    .........Section 1003(a)(iv) of the Company Guide which states that the Exchange will normally consider suspending dealings in, or remove from listing, a company that has sustained losses which are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the Exchange, as to whether such company will be able to continue operations and/or meet its obligations as they mature...........can it get any uglier....geesh...

CVM
1.27-0.01(-0.78%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT
Advanced Micro Devices, Inc.
NYSEThu, Apr 17, 2014 4:00 PM EDT
SandRidge Energy, Inc.
NYSEThu, Apr 17, 2014 4:01 PM EDT